Login to Your Account

Zafgen files $86.25M IPO to advance obesity candidate beloranib

By Marie Powers
Staff Writer

Monday, April 21, 2014
Zafgen Inc. defied recent trends to downsize biotech initial public offerings (IPO) by filing with the SEC to seek a raise of up to $86.25 million, excluding overallotments. If the offering amount stands, Zafgen would slide into a tie with Radius Health Inc. for third place among 22 biotechs sitting in the IPO queue.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription